Manipulation of immune regulatory pathways has been proven to be effective in different subsets of sarcomas with paradigmatic immune-sensitive/“hot” tumors, which harbor high levels of tumor mutational burden (TMB), CD8+ lymphocytes and programmed death-ligand 1 (PD-L1) expression [17–19] and are thus sensitive to ICIs. This evidence concerns the gene CD274 and neoplasm.